The MICU2 Knockout Raji Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population generated from the human Raji B lymphocyte cell line, targeting the MICU2 gene. This heterogeneous pool provides a loss-of-function model that circumvents clonal selection bias, enabling robust evaluation of MICU2-dependent regulation of the mitochondrial calcium uniporter (MCU) complex within a Burkitt lymphoma context.
The Raji host cell line is an Epstein-Barr virus (EBV)-positive human B lymphocyte line originally established from a Burkitt lymphoma patient. Raji cells retain characteristic B cell features, including surface immunoglobulin expression and antigen presentation capacity, and are widely utilized to study humoral immunity, lymphocyte activation, and lymphomagenesis. Their rapid proliferation and transformed metabolic state make them a suitable platform for dissecting mitochondrial contributions to B cell biology and oncogenesis.
MICU2 functions as a regulatory subunit of the MCU complex, forming a heterodimer with MICU1 to set the threshold for mitochondrial Ca2+ uptake. Under low cytosolic Ca2+, MICU2 constrains MCU activity to prevent overload. Its regulation involves upstream factors such as PGC-1??, NRF-1, and ATP/ADP balance, and it requires interactions with MCU, EMRE, and MCUR1. MICU2 disruption leads to unregulated mitochondrial Ca2+ influx, hyperactivation of pyruvate dehydrogenase and isocitrate dehydrogenase, elevated ROS, and sensitization to cytochrome c release and caspase-mediated apoptosis.
In the Raji B cell model, loss of MICU2 gatekeeping disrupts mitochondrial calcium homeostasis, potentially shifting metabolic programming and altering apoptotic thresholds. B cell lymphomas frequently co-opt mitochondrial dynamics to support survival and proliferation; accordingly, this polyclonal knockout model facilitates investigation of how MCU complex dysregulation contributes to lymphomagenesis. Researchers can explore the crosstalk between calcium signaling, oxidative stress, and cell death pathways in an EBV-driven malignancy background, uncovering mitochondrial vulnerabilities.
Key assays include mitochondrial calcium uptake (Rhod-2 AM), apoptosis (Annexin V/PI), ATP bioluminescence, ROS detection (DCFDA), and mitochondrial membrane potential (TMRE). Co-immunoprecipitation reveals MCU complex interactions, while RT-qPCR and Western blotting confirm knockout. Applications encompass mitochondrial calcium signaling research, B cell lymphoma pathobiology, drug screening targeting the MCU complex, and immunometabolism. Contact Ascent Research for technical inquiries.
